Sugi Predict

Sugi Predict / Compounds / SCHEMBL625240

SCHEMBL625240

SCHEMBL625240

CC(O)Cc1ccccc1Br

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TAAR1 Q96RJ0 3/20 0.44
▸ IDO1 P14902 2/20 0.42
▸ PPARG P37231 1/20 0.41
▸ PPARA Q07869 1/20 0.41
▸ TSHR P16473 2/20 0.40
▸ SLC6A2 P23975 1/20 0.39
▸ SLC6A4 P31645 1/20 0.39
▸ GABRA1 P14867 1/20 0.39
▸ GABRB2 P47870 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ ANPEP P15144 1/20 0.39
▸ LMNA P02545 1/20 0.38
▸ PYCR1 P32322 1/20 0.38
▸ RIPK1 Q13546 1/20 0.38
▸ CYP1A2 P05177 1/20 0.37
▸ CYP2D6 P10635 1/20 0.37
▸ NFKB1 P19838 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14997308 1.00 TAAR1 (0.44) TAAR1IDO1PPARGPPARATSHR
SCHEMBL15319327 1.00 TAAR1 (0.44) TAAR1IDO1PPARGPPARATSHR
SCHEMBL29679614 1.00 TAAR1 (0.44) TAAR1IDO1PPARGPPARATSHR
SCHEMBL21777255 0.85 TAAR1 (0.47) TAAR1IDO1PPARGPPARATSHR
SCHEMBL5988255 0.84 GABRA1 (0.46) TAAR1SLC6A2SLC6A4GABRA1GABRB2
SCHEMBL21777254 0.83 TAAR1 (0.41) TAAR1IDO1PPARGPPARATSHR
SCHEMBL10701084 0.82 TAAR1 (0.46) TAAR1IDO1PPARGPPARATSHR
SCHEMBL4685387 0.82 GABRA1 (0.52) TAAR1IDO1PPARGPPARATSHR
SCHEMBL22474553 0.82 GABRA1 (0.53) TSHRSLC6A2GABRA1GABRB2HPGD
SCHEMBL28330984 0.82 GABRA1 (0.39) TAAR1GABRA1GABRB2HPGDANPEP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4663189-A2 FUSED TRICYCLIC COMPOUND AND MEDICINAL USE THEREOF Japan Tobacco Inc. (JP) 2025-12-17 — — EP disclosed
US-20250340516-A1 Isoquinolinones as Modulators of POLRMT PRETZEL THERAPEUTICS, INC. (US) 2025-11-06 — — US disclosed
EP-4116301-B1 FUSED TRICYCLIC COMPOUND AND MEDICINAL USE THEREOF JAPAN TOBACCO INC (JP) 2025-10-08 — — EP disclosed
US-20230025880-A1 FUSED TRICYCLIC COMPOUND AND MEDICINAL USE THEREOF JAPAN TOBACCO INC. (JP) 2023-01-26 — — US disclosed
US-20230025880-A1 FUSED TRICYCLIC COMPOUND AND MEDICINAL USE THEREOF JAPAN TOBACCO INC. (JP) 2023-01-26 — — US disclosed
EP-4116301-A1 FUSED TRICYCLIC COMPOUND AND MEDICINAL USE THEREOF Japan Tobacco Inc. (JP) 2023-01-11 — — EP disclosed
EP-4116301-A1 FUSED TRICYCLIC COMPOUND AND MEDICINAL USE THEREOF Japan Tobacco Inc. (JP) 2023-01-11 — — EP disclosed
CN-115151543-A Fused tricyclic compounds and medical use thereof 日本烟草产业株式会社 2022-10-04 — — CN disclosed
CN-110526802-B Monomer, polymer, negative resist composition, photomask blank, and resist pattern forming method 信越化学工业株式会社 2022-09-20 — — CN disclosed
CN-112694449-B Asymmetric hydrogenation of ketone and alpha, beta-unsaturated ketone catalyzed by nonmetal catalyst 中国科学院化学研究所 2022-05-24 — — CN disclosed
US-7034015-B2 Interleukin 1 beta and tumour necrosis factor alpha inhibitors LEO PHARMA A/S (DK) 2006-04-25 — — US disclosed
EP-1313560-A4 CATALYST FOR AROMATIC C-O, C-N, and C-C BOND FORMATION UNIV YALE (US) 2005-02-09 — — EP disclosed
CN-1561327-A Novel aminobenzophenones LEO PHARMA AS (DK) 2005-01-05 — — CN disclosed
EP-1423356-A2 NOVEL AMINOBENZOEPHENONES Leo Pharma A/S (DK) 2004-06-02 — — EP disclosed
US-20030119902-A1 Interleukin 1 beta and tumour necrosis factor alpha inhibitors LEO PHARMA A/S (DK) 2003-06-26 — — US disclosed
EP-1313560-A1 CATALYST FOR AROMATIC C-O, C-N, and C-C BOND FORMATION YALE UNIVERSITY (US) 2003-05-28 — — EP disclosed
US-6562989-B2 Bicyclopentyl iron ligand and transition metal catalyst YALE UNIVERSITY 2003-05-13 — — US disclosed
WO-2003018535-A2 NOVEL AMINOBENZOEPHENONES LEO PHARMA A/S (DK) 2003-03-06 — — WO disclosed
US-20030008768-A1 Catalyst for aromatic C-O, C-N, and C-C bond formation NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-01-09 — — US disclosed
WO-2002011883-A1 CATALYST FOR AROMATIC C-O, C-N, and C-C BOND FORMATION YALE UNIVERSITY (US) 2002-02-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230025880-A1 FUSED TRICYCLIC COMPOUND AND MEDICINAL USE THEREOF PC, PCK2, AGK TAAR1 4664/4885IDO1 3667/4885PPARG 224/4885
US-20250340516-A1 Isoquinolinones as Modulators of POLRMT POLRMT, TFAM, UQCRC1 TAAR1 3994/4885IDO1 2113/4885PPARG 845/4885
US-20030119902-A1 Interleukin 1 beta and tumour necrosis factor alpha inhibitors IL1B, IL1A, TNF TAAR1 3169/4885IDO1 323/4885PPARG 1923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.